{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-112841","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.676986+00:00","generated_at":"2026-05-30T07:43:53.132261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck Q3 2024: GAAP EPS $1.24, Non-GAAP $1.57; Sales $16.7B (+4% YoY)","bullets":["Total worldwide sales $16.7B, up 4% (7% ex-FX). GAAP EPS $1.24; Non-GAAP EPS $1.57.","KEYTRUDA sales $7.4B (+17% / 21% ex-FX). WINREVAIR sales $149M, gaining momentum.","FY2024 guidance narrowed: sales $63.6B-$64.1B; Non-GAAP EPS $7.72-$7.77, includes $0.24/share net charge from Curon and Daiichi Sankyo deals.","R&D expenses surged 77% to $5.9B, driven by $1.35B EyeBio acquisition and $750M Curon asset purchase.","GARDASIL/GARDASIL 9 sales fell 11% due to lower China demand; Animal Health up 6% (11% ex-FX)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-112841","json":"https://secwatch.observer/filing/0001104659-24-112841.json","markdown":"https://secwatch.observer/filing/0001104659-24-112841.md","text":"https://secwatch.observer/filing/0001104659-24-112841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465924112841/0001104659-24-112841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465924112841/tm2426878d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:43:53.132261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}